prs-220 (Charles River Laboratories)
90
Structured Review
Charles River Laboratories
prs-220
Prs 220, supplied by Charles River Laboratories, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/prs-220/prs+220/pm40185752-279-21-11
Average 90 stars, based on 1 article reviews
Prs 220, supplied by Charles River Laboratories, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/prs-220/prs+220/pm40185752-279-21-11
Average 90 stars, based on 1 article reviews
prs-220 - by Bioz Stars,
2026-10
90/100 stars
Images
Related Articles
Injection:Article Title: Preclinical concept studies showing advantage of an inhaled anti-CTGF/CCN2 protein for pulmonary fibrosis treatment. Article Snippet: Pharmacokinetic analysis of PRS-220 and pamrevlumab in mice Male C57BL/6N mice ( Ex Vivo:Article Title: Preclinical concept studies showing advantage of an inhaled anti-CTGF/CCN2 protein for pulmonary fibrosis treatment. Article Snippet: Pharmacokinetic analysis of PRS-220 and pamrevlumab in mice Male C57BL/6N mice ( Inhibition:Article Title: Preclinical concept studies showing advantage of an inhaled anti-CTGF/CCN2 protein for pulmonary fibrosis treatment. Article Snippet: Pharmacokinetic analysis of PRS-220 and pamrevlumab in mice Male C57BL/6N mice ( Titration:Article Title: Preclinical concept studies showing advantage of an inhaled anti-CTGF/CCN2 protein for pulmonary fibrosis treatment. Article Snippet: Pharmacokinetic analysis of PRS-220 and pamrevlumab in mice Male C57BL/6N mice ( Incubation:Article Title: Preclinical concept studies showing advantage of an inhaled anti-CTGF/CCN2 protein for pulmonary fibrosis treatment. Article Snippet: Pharmacokinetic analysis of PRS-220 and pamrevlumab in mice Male C57BL/6N mice ( Concentration Assay:Article Title: Preclinical concept studies showing advantage of an inhaled anti-CTGF/CCN2 protein for pulmonary fibrosis treatment. Article Snippet: Pharmacokinetic analysis of PRS-220 and pamrevlumab in mice Male C57BL/6N mice ( Software:Article Title: Preclinical concept studies showing advantage of an inhaled anti-CTGF/CCN2 protein for pulmonary fibrosis treatment. Article Snippet: Pharmacokinetic analysis of PRS-220 and pamrevlumab in mice Male C57BL/6N mice ( Fluorescence:Article Title: Preclinical concept studies showing advantage of an inhaled anti-CTGF/CCN2 protein for pulmonary fibrosis treatment. Article Snippet: Pharmacokinetic analysis of PRS-220 and pamrevlumab in mice Male C57BL/6N mice ( Imaging:Article Title: Preclinical concept studies showing advantage of an inhaled anti-CTGF/CCN2 protein for pulmonary fibrosis treatment. Article Snippet: Pharmacokinetic analysis of PRS-220 and pamrevlumab in mice Male C57BL/6N mice ( Labeling:Article Title: Preclinical concept studies showing advantage of an inhaled anti-CTGF/CCN2 protein for pulmonary fibrosis treatment. Article Snippet: Pharmacokinetic analysis of PRS-220 and pamrevlumab in mice Male C57BL/6N mice ( Staining:Article Title: Preclinical concept studies showing advantage of an inhaled anti-CTGF/CCN2 protein for pulmonary fibrosis treatment. Article Snippet: Pharmacokinetic analysis of PRS-220 and pamrevlumab in mice Male C57BL/6N mice ( Binding Assay:Article Title: Preclinical concept studies showing advantage of an inhaled anti-CTGF/CCN2 protein for pulmonary fibrosis treatment. Article Snippet: Pharmacokinetic analysis of PRS-220 and pamrevlumab in mice Male C57BL/6N mice ( Electrochemiluminescence:Article Title: Preclinical concept studies showing advantage of an inhaled anti-CTGF/CCN2 protein for pulmonary fibrosis treatment. Article Snippet: Pharmacokinetic analysis of PRS-220 and pamrevlumab in mice Male C57BL/6N mice ( |